These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20224288)

  • 21. Neuroprotective therapy in Parkinson disease.
    Chen S; Le W
    Am J Ther; 2006; 13(5):445-57. PubMed ID: 16988541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rasagiline -- is there a place for this drug in managing Parkinson's disease?
    Sharma JC
    Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281
    [No Abstract]   [Full Text] [Related]  

  • 23. DATATOP-study: significance of its results in the treatment of Parkinson's disease.
    Schneider E
    J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical aspects of neuroprotection in Parkinson's disease.
    Przuntek H
    J Neural Transm Suppl; 1994; 43():163-9. PubMed ID: 7884398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME
    J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract]   [Full Text] [Related]  

  • 30. [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].
    Linazasoro G; Sesar A; Valldeoriola F; Compta Y; Herrero MT; Martínez Castrillo JC; López Lozano JJ; Bergaretxe A; Vela L; Fernández JM; Castro A; Kulisevski J; Lezcano E; Vaamonde J; López Del Val J; Chacón J; Vivancos F; Luquin R; Aguilar M; Burguera JA; Salvador C; Menéndez Guisasola L; Catalán MJ; Mir P; Campos V; Grandas F; Mínguez A; Balaguer E; Yáñez R; Leiva C; García Ruiz P; Cubo E
    Neurologia; 2009 Mar; 24(2):113-24. PubMed ID: 19322690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New drugs in the future treatment of Parkinson's disease.
    Djaldetti R; Melamed E
    J Neurol; 2002 Sep; 249 Suppl 2():II30-5. PubMed ID: 12375061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New drug treatment for Parkinson's disease.
    FDA Consum; 2006; 40(4):7. PubMed ID: 17245831
    [No Abstract]   [Full Text] [Related]  

  • 33. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A responsive outcome for Parkinson's disease neuroprotection futility studies.
    Elm JJ; Goetz CG; Ravina B; Shannon K; Wooten GF; Tanner CM; Palesch YY; Huang P; Guimaraes P; Kamp C; Tilley BC; Kieburtz K;
    Ann Neurol; 2005 Feb; 57(2):197-203. PubMed ID: 15668964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.
    Meissner W; Hill MP; Tison F; Gross CE; Bezard E
    Trends Pharmacol Sci; 2004 May; 25(5):249-53. PubMed ID: 15120490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Where do we stand on neuroprotection? Where do we go from here?
    Shoulson I
    Mov Disord; 1998; 13 Suppl 1():46-8. PubMed ID: 9613718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.
    de la Fuente-Fernández R; Schulzer M; Mak E; Sossi V
    Parkinsonism Relat Disord; 2010 Jul; 16(6):365-9. PubMed ID: 20471298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurotoxicity and neuroprotection in Parkinson's disease.
    Lange KW; Youdim MB; Riederer P
    J Neural Transm Suppl; 1992; 38():27-44. PubMed ID: 1491247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug therapy of Parkinson's disease].
    Myllylä V
    Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.